↓ Skip to main content

Dove Medical Press

Eribulin mesylate in the treatment of metastatic breast cancer

Overview of attention for article published in Biologics: Targets & Therapy, January 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#25 of 284)
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
1 news outlet
patent
2 patents

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
49 Mendeley
Title
Eribulin mesylate in the treatment of metastatic breast cancer
Published in
Biologics: Targets & Therapy, January 2012
DOI 10.2147/btt.s19811
Pubmed ID
Authors

Sarika Jain, Tessa Cigler

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Portugal 1 2%
Unknown 47 96%

Demographic breakdown

Readers by professional status Count As %
Other 17 35%
Researcher 5 10%
Student > Postgraduate 4 8%
Student > Bachelor 3 6%
Student > Doctoral Student 2 4%
Other 3 6%
Unknown 15 31%
Readers by discipline Count As %
Medicine and Dentistry 19 39%
Biochemistry, Genetics and Molecular Biology 4 8%
Chemistry 3 6%
Agricultural and Biological Sciences 3 6%
Linguistics 1 2%
Other 3 6%
Unknown 16 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2020.
All research outputs
#2,655,696
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#25
of 284 outputs
Outputs of similar age
#19,267
of 250,101 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 2 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,101 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them